[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metabolic-and-bariatric-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metabolic-and-bariatric-surgery":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100587920","phase-3-early-re-initiation-of-semaglutide-post-sleeve-gastrectomy-in-youth-100587920",false,"NCT06934655","Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth","Inclusion Criteria:\n\n* ages 12 to 18 years\n* Tanner stage 3 or higher\n* severe obesity (defined as a BMI greater than 35 kg\u002Fm2 or BMI ≥140% of the 95th percentile)\n* currently undergoing primary surgical weight loss through the pediatric bariatric surgery pathway at Children's Hospital Los Angeles\n* be willing to have blood collected before and after surgical procedure at defined points\n* be willing to have clinical data entered into a prospective database; 8) presence of a consenting caregiver\n* be taking semaglutide 2.4 mg weekly as part of their routine medical care prior to surgery as part of their obesity treatment program, apart from any planned surgical procedure.\n\nExclusion Criteria:\n\n* have a previous diagnosis of type 1 diabetes\n* taking any medications known to influence body composition or prevent weight loss or promote weight gain (e.g. prednisone)\n* have been diagnosed with syndromes or diseases that may influence the postoperative course (e.g., Cushing syndrome, Down syndrome, Prader Willi Syndrome)\n* have significant comorbid medical conditions necessitating frequent hospitalization that may require interruption of medications and\u002For that would make early re-initiation of semaglutide unsafe due to the other medical comorbidities\n* refuse to comply with eligibility criteria.","ALL","12 Years","18 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This is a Phase 3a, randomized, parallel-controlled trial designed to compare the early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery). The trial will involve 150 youth with severe obesity who have been on semaglutide 2.4 mg weekly for at least 3 months prior to surgery. Participants will be randomized to either (1) semaglutide 2.4 mg weekly or (2) standard care for 24 months. Primary, secondary, and tertiary outcomes will be assessed at multiple time points: 1-month, day of surgery, and 1-, 3-, 6-, 9-, 12-, 18-, and 24-months postoperatively. We hypothesize that early re-initiation of semaglutide will be safe, well-tolerated, and lead to greater improvements in obesity, cardiometabolic risk, and eating behaviors.",[26,27,28],"Pediatric Obesity","Metabolic and Bariatric Surgery","Semaglutide","NOT_YET_RECRUITING","2026-03-16",{"date":32,"type":33},"2026-03-17","ACTUAL",{"date":35,"type":20},"2026-06-01",{"date":37,"type":20},"2033-11-01",{"name":39,"class":40},"Children's Hospital Los Angeles","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":41},"100579829","tailored-one-anastomosis-gastric-bypass-100579829","NCT06829381","Tailored One Anastomosis Gastric Bypass","Tailoring One-Anastomosis Gastric Bypass Based on Total Small Bowel Length - A Randomized Controlled Trial","OAGB-TL","Inclusion Criteria:\n\n* Adults (≥18 years) undergoing OAGB\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years, pregnant women, or those lacking decision-making capacity Prior bariatric surgery Short bowel (\\\u003C450 cm)",{"count":51,"type":20},500,[53],"NA","One Anastomosis Gastric Bypass (OAGB) is the most common metabolic and bariatric surgery (MBS) in Israel, recognized for its effectiveness in achieving sustainable weight loss and mitigating obesity-related diseases. The metabolic outcomes of OAGB are significantly influenced by the length of the biliopancreatic limb (BPL). The objective of this study is to determine whether tailoring the BPL length to the total small bowel length (TSBL) results in more effective weight loss compared to patients undergoing OAGB with a fixed BPL of 180 cm. Efficacy and safety of this approach will also be evaluated, ensuring it does not lead to long-term morbidity or negatively impact patients' quality of life.",[27],[57,58,59,60],"one anastomosis gastric bypass","obesity","weight loss","tailoring","RECRUITING","2025-07-21",{"date":64,"type":33},"2025-07-24",{"date":66,"type":33},"2025-01-29",{"date":68,"type":20},"2029-01-31",{"name":70,"class":71},"Tel-Aviv Sourasky Medical Center","OTHER_GOV"]